Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

7.94
-0.4600-5.48%
Pre-market: 8.060.1200+1.51%04:45 EDT
Volume:4.80M
Turnover:38.31M
Market Cap:1.02B
PE:-2.09
High:8.47
Open:8.45
Low:7.79
Close:8.40
52wk High:31.35
52wk Low:3.76
Shares:129.00M
Float Shares:97.15M
Volume Ratio:1.20
T/O Rate:4.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8005
EPS(LYR):-2.8616
ROE:-93.65%
ROA:-45.34%
PB:2.27
PE(LYR):-2.77

Loading ...

Small U.S. Stocks Decrease; Alumis Takes Biggest Hit

Dow Jones
·
Sep 02

Alumis price target lowered to $27 from $35 at Baird

TIPRANKS
·
Sep 02

Top Midday Decliners

MT Newswires Live
·
Sep 02

Alumis price target lowered to $25 from $51 at Wells Fargo

TIPRANKS
·
Sep 02

Alumis falls -58.9%

TIPRANKS
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

Alumis Down over 54%, on Pace for Record Percent Decrease

Dow Jones
·
Sep 01

Alumis Set for Worst Day After Lupus Drug Misses Main Goal in Mid-Stage Trial

Reuters
·
Sep 01

Alumis Eyes Late-Stage Lupus Study Despite Trial Miss

Reuters
·
Sep 01

Alumis Reports Phase 2b Envudeucitinib Data in Lupus

TIPRANKS
·
Sep 01

Alumis' Lupus Drug Fails Mid-Stage Trial Goal

Reuters
·
Sep 01

Alumis Says Phase 2b LUMUS Trial of Envudeucitinib in Systemic Lupus Erythematosus Misses Primary Endpoint

Reuters
·
Sep 01

Alumis - Envudeucitinib Well Tolerated with no New Safety Signals in Lumus Trial

THOMSON REUTERS
·
Sep 01

Alumis - Lumus Phase 2B Trial of Envudeucitinib Did not Meet Primary and Secondary Endpoints

THOMSON REUTERS
·
Sep 01

Alumis - Robust Responses in Ifngs-High Subgroup Support Phase 3 Development of Envudeucitinib in Sle

THOMSON REUTERS
·
Sep 01

Alumis - on Track to Submit Nda for Envudeucitinib in Plaque Psoriasis in Q4 2026

THOMSON REUTERS
·
Sep 01

Alumis Announces Topline Results from Envudeucitinib Phase 2B Trial in Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS
·
Sep 01

Alumis Inc. - Actively Evaluating Opportunities to Maximize Value of Our Oral Tyk2 Portfolio

THOMSON REUTERS
·
Sep 01

NASDAQ Trade Halt Halt News Pending at 07:25 Am

Reuters
·
Sep 01

What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders

Simply Wall St.
·
Aug 19